Fig 5 - by Hannah N. Marmor (14046394)

<i>tusB</i> overexpression promotes <i>Y</i>. <i>pseudotuberculosis</i> doxycycline sensitivity <i>in vitro</i>. by Hector S. Alvarez-Manzo (12551730)

Tun increases mitochondrial fission, inflammatory cell infiltration, and decreased ER-mitochondria interaction in neonatal rat lungs. by Kirkwood A. Pritchard Jr. (13449794)

“…The decreased expressions of GRP75 (0.5±0.2-fold, p = 0.006767, n = 5) and acyl-CoA synthetase long-chain family member 4 (ASCL4; 0.3±0.1-fold, p<0.001, n = 5) indicate a decreased interaction between ER and mitochondria by Tun. …”

Pravastatin increases cyclin D1 expression but prevents passage through S-Phase in NSPCs. by Ross A. Carson (5184512)

The results of assay of blood serum biochemical parameters after experiment. by Fatima Dikhanbayeva (11501962)

“…(A) TP decreased in groups III, IV, V, but increased in group II compared to group I. …”

Pig growth over the course of the experiment. by James H. Bishop (2182486)

Probability of neutropenic-related event based on cycle 1 nadir ANC and average hemoglobin decrease at each sample by Edgardo Rivera (55591)

Nitrile in the Hole: Discovery of a Small Auxiliary Pocket in Neuronal Nitric Oxide Synthase Leading to the Development of Potent and Selective 2‑Aminoquinoline Inhibitors by Maris A. Cinelli (1309419)

“…We previously developed a class of membrane-permeable 2-aminoquinoline inhibitors and later rearranged the scaffold to decrease off-target binding. …”

Upregulated genes in the thalamus of the mouse exposed sound stress (fold change > 1.5). by Satoka Kasai (3861115)

Results of peptide toxicity of each diet. by Fatima Dikhanbayeva (11501962)

“…<p>Values are given as mean ± SD for a total of 50 animals. Control group (I) - 0.295 nm, Curd mass (II)– 0.122 nm, Curd mass with flaxseed flour (III)– 0.113 nm, curd mass with celery root powder (IV) - 0.114 nm, Curd mass with bee bread (V)– 0.127 nm. …”

A647D decreased mexiletine sensitivity of P1332L when coexpressed. by Jie Liu (15128)

The proportional decrease in chamber area with depth of nests is similar no matter what the colony size by Walter R. Tschinkel (2765)

Downhill Running-Based Overtraining Protocol Improves Hepatic Insulin Signaling Pathway without Concomitant Decrease of Inflammatory Proteins - Fig 2 by Alisson L. da Rocha (804331)

Effect of DFATs implantation on the inhibition of atrophy in the atrophic vocal fold muscle. by Ikuo Mikoshiba (9312007)

Subjects:

The activity of platelet P2Y1, but not of P2X1 or P2Y12 receptor, continually decreases in citrated WB. by Juergen Koessler (847843)

Monoclonal antibody inhibition of IL-8 and CXCR2 decreased TFF3 stimulated HUVEC tubule formation <i>in vitro</i>. by Wai-Hoe Lau (825097)

Image4_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

“…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”

Image2_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

“…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”

Image6_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

“…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”

Image3_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

“…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”